Popov Mikhail

Dr. Popov Mikhail

Cardiosurgery, Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in Mitochondrion
Verified
Journal Article
Closed access
ABAlexander V. Blagov
Alexander V. Blagov
VSVolha Summerhill
Volha Summerhill
Vasily N SukhorukovVasily N Sukhorukov
Vasily N Sukhorukov
Popov MikhailPopov Mikhail
Popov Mikhail
AGAndrey Grechko
Andrey Grechko
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov

29 July 2022 in Electrophoresis
Verified
Journal Article
Closed access
AIAlexander Ivanov
Alexander Ivanov
Popov MikhailPopov Mikhail
Popov Mikhail
VAValery Vasil'Evich Aleksandrin
Valery Vasil'Evich Aleksandrin
LKLubov Mikhailovna Kozhevnikova
Lubov Mikhailovna Kozhevnikova
AMAlexey Aleksandrovich Moskovtsev
Alexey Aleksandrovich Moskovtsev
AKAslan Amirkhanovich Kubatiev
Aslan Amirkhanovich Kubatiev

1 January 2023 in Journal of Lipid and Atherosclerosis
Verified
Journal Article
Open access
PDF file
APAnastasia Poznyak
Anastasia Poznyak
Vasily N SukhorukovVasily N Sukhorukov
Vasily N Sukhorukov
Popov MikhailPopov Mikhail
Popov Mikhail
ECEgor Chegodaev
Egor Chegodaev
APAnton Postnov
Anton Postnov
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
Poznyak AV, et al. J Lipid Atheroscler. 2023 Sep;12(3):223-236. https://doi.org/10.12997/jla.2023.12.3.223

1 January 2023 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
APAnastasia Poznyak
Anastasia Poznyak
DKDmitry Kashirskikh
Dmitry Kashirskikh
APAnton Postnov
Anton Postnov
Popov MikhailPopov Mikhail
Popov Mikhail
Vasily N SukhorukovVasily N Sukhorukov
Vasily N Sukhorukov
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
In the modern world, cardiovascular diseases have a special place among the most common causes of death. Naturally, this widespread problem cannot escape the attention of scientists and researchers. One of the main conditions preceding the development of fatal cardiovascular diseases is atherosclerosis. Despite extensive research into its pathogenesis and possible prevention and treatment strategies, many gaps remain in our understanding of this disease. For example, the concept of multiple low-density lipoprotein modifications was recently stated, in which desialylation is of special importance. Apart from this, sialic acids are known to be important contributors to processes such as endothelial dysfunction and inflammation, which in turn are major components of atherogenesis. In this review, we have collected information on sialic acid metabolism, analyzed various aspects of its implication in atherosclerosis at different stages, and provided an overview of the role of particular groups of enzymes responsible for sialic acid metabolism in the context of atherosclerosis.

Verified
Journal Article
Open access
PDF file
APAnastasia Poznyak
Anastasia Poznyak
VOVarvara Orekhova
Varvara Orekhova
Vasily N SukhorukovVasily N Sukhorukov
Vasily N Sukhorukov
VKVictoria A. Khotina
Victoria A. Khotina
Popov MikhailPopov Mikhail
Popov Mikhail
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
Atherosclerosis is a major global health problem. Being a harbinger of a large number of cardiovascular diseases, it ultimately leads to morbidity and mortality. At the same time, effective measures for the prevention and treatment of atherosclerosis have not been developed, to date. All available therapeutic options have a number of limitations. To understand the mechanisms behind the triggering and development of atherosclerosis, a deeper understanding of molecular interactions is needed. Heat shock proteins are important for the normal functioning of cells, actively helping cells adapt to gradual changes in the environment and survive in deadly conditions. Moreover, multiple HSP families play various roles in the progression of cardiovascular disorders. Some heat shock proteins have been shown to have antiatherosclerotic effects, while the role of others remains unclear. In this review, we considered certain aspects of the antiatherosclerotic activity of a number of heat shock proteins.

Verified
Journal Article
Open access
PDF file
ADAlexander D. Dergunov
Alexander D. Dergunov
ENElena Nosova
Elena Nosova
ARAlexandra V. Rozhkova
Alexandra V. Rozhkova
MVMargarita A. Vinogradina
Margarita A. Vinogradina
VBVeronika Baserova
Veronika Baserova
LDLyudmila V. Dergunova
Lyudmila V. Dergunova
Differential expression of genes (DEGs) in coronary artery disease (CAD) and the association between transcript level and high-density lipoprotein cholesterol (HDL-C) were studied with 76 male patients with CAD and 63 control patients. The transcript level of genes related to HDL metabolism (24 genes) and atherosclerosis-prone (41 genes) in RNA isolated from peripheral blood mononuclear cells was measured by real-time RT-PCR. Twenty-eight DEGs were identified. The expression of cholesterol transporters, ALB, APOA1, and LCAT was down-regulated, while the expression of AMN, APOE, LDLR, LPL, PLTP, PRKACA, and CETP was up-regulated. The systemic inflammation in CAD is evidenced by the up-regulation of IL1B, TLR8, CXCL5, and TNFRSF1A. For the controls, TLR8 and SOAT1 were negative predictors of the HDL-C level. For CAD patients, PRKACG, PRKCQ, and SREBF1 were positive predictors, while PRKACB, LCAT, and S100A8 were negative predictors. For CAD patients, the efficiency of reverse cholesterol transport is 73–79%, and intracellular free cholesterol seems to accumulate at hyperalphalipoproteinemia. Both atheroprotective (via S100A8) and proatherogenic (via SREBF1, LCAT, PRKACG, PRKACB, and PRKCQ) associations of gene expression with HDL-C determine HDL functionality in CAD patients. The selected key genes and involved pathways may represent HDL-specific targets for the diagnosis and treatment of CAD and atherosclerosis.